Insider Transactions in Q1 2023 at Apellis Pharmaceuticals, Inc. (APLS)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 30
2023
|
Karen Lewis Chief People Officer |
SELL
Open market or private sale
|
Direct |
883
-2.36%
|
$45,916
$52.76 P/Share
|
|
Jan 27
2023
|
David O. Watson General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
551
-0.33%
|
$28,652
$52.77 P/Share
|
|
Jan 27
2023
|
Timothy Eugene Sullivan Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
551
-0.44%
|
$28,652
$52.77 P/Share
|
|
Jan 27
2023
|
Adam J. Townsend Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
551
-0.8%
|
$28,652
$52.77 P/Share
|
|
Jan 27
2023
|
Karen Lewis Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
367
-0.97%
|
$19,084
$52.77 P/Share
|
|
Jan 27
2023
|
Nur Nicholson Chief Technical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
551
-1.0%
|
$28,652
$52.77 P/Share
|
|
Jan 27
2023
|
Lukas Scheibler Chief Research Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
542
-0.88%
|
$28,184
$52.77 P/Share
|
|
Jan 27
2023
|
Jeffrey Eisele Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
367
-0.77%
|
$19,084
$52.77 P/Share
|
|
Jan 27
2023
|
Cedric Francois Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,879
-0.28%
|
$149,708
$52.77 P/Share
|
|
Jan 27
2023
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
367
-0.77%
|
$19,084
$52.77 P/Share
|
|
Jan 27
2023
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
832
-0.08%
|
$43,264
$52.77 P/Share
|
|
Jan 23
2023
|
Jeffrey Eisele Chief Development Officer |
SELL
Open market or private sale
|
Direct |
4,479
-8.58%
|
$228,429
$51.58 P/Share
|
|
Jan 23
2023
|
Karen Lewis Chief People Officer |
SELL
Open market or private sale
|
Direct |
2,955
-7.27%
|
$150,705
$51.58 P/Share
|
|
Jan 20
2023
|
Adam J. Townsend Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,912
-2.72%
|
$99,424
$52.05 P/Share
|
|
Jan 20
2023
|
David O. Watson General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
2,034
-1.2%
|
$105,768
$52.05 P/Share
|
|
Jan 20
2023
|
Karen Lewis Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,411
-3.35%
|
$73,372
$52.05 P/Share
|
|
Jan 20
2023
|
Nur Nicholson Chief Technical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,034
-3.57%
|
$105,768
$52.05 P/Share
|
|
Jan 20
2023
|
Lukas Scheibler Chief Research Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,015
-3.16%
|
$104,780
$52.05 P/Share
|
|
Jan 20
2023
|
Timothy Eugene Sullivan Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,379
-1.87%
|
$123,708
$52.05 P/Share
|
|
Jan 20
2023
|
Jeffrey Eisele Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,033
-3.75%
|
$105,716
$52.05 P/Share
|
|
Jan 20
2023
|
Cedric Francois Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,453
-0.9%
|
$491,556
$52.05 P/Share
|
|
Jan 20
2023
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,149
-2.36%
|
$59,748
$52.05 P/Share
|
|
Jan 20
2023
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,326
-0.23%
|
$120,952
$52.05 P/Share
|
|
Jan 20
2023
|
Victoria L. Brown Program Team Lead |
SELL
Payment of exercise price or tax liability
|
Direct |
1,412
-5.66%
|
$73,424
$52.05 P/Share
|
|
Jan 20
2023
|
James George Chopas VP/Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
919
-3.27%
|
$47,788
$52.05 P/Share
|
|
Jan 17
2023
|
Alec Machiels Director |
SELL
Open market or private sale
|
Direct |
1,250
-0.46%
|
$65,000
$52.42 P/Share
|
|
Jan 17
2023
|
Alec Machiels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+0.46%
|
$2,500
$2.67 P/Share
|
|
Jan 12
2023
|
James George Chopas VP/Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,621
+25.52%
|
-
|
|
Jan 12
2023
|
Timothy Eugene Sullivan Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
27,488
+17.78%
|
-
|
|
Jan 12
2023
|
Nur Nicholson Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,580
+28.36%
|
-
|
|
Jan 12
2023
|
Lukas Scheibler Chief Research Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,580
+26.17%
|
-
|
|
Jan 12
2023
|
Adam J. Townsend Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
27,488
+28.08%
|
-
|
|
Jan 12
2023
|
David O. Watson General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
53,455
+14.76%
|
-
|
|
Jan 12
2023
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,634
+1.92%
|
-
|
|
Jan 12
2023
|
Jeffrey Eisele Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,580
+29.4%
|
-
|
|
Jan 12
2023
|
Cedric Francois Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
83,447
+7.37%
|
-
|
|
Jan 12
2023
|
Karen Lewis Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,634
+31.82%
|
-
|
|
Jan 12
2023
|
Mark Jeffrey De Long Chief Business & Strat Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,634
+28.74%
|
-
|
|
Jan 09
2023
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
12,000
-1.21%
|
$552,000
$46.08 P/Share
|
|
Jan 09
2023
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,500
+1.82%
|
$37,000
$2.67 P/Share
|
|
Jan 05
2023
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,500
-2.57%
|
$120,000
$48.79 P/Share
|
|
Jan 03
2023
|
Adam J. Townsend Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
5,000
-10.44%
|
$250,000
$50.7 P/Share
|
|
Jan 03
2023
|
Adam J. Townsend Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+9.45%
|
$75,000
$15.09 P/Share
|
|
Jan 03
2023
|
Caroline Baumal Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,549
+49.91%
|
-
|
|
Jan 03
2023
|
A. Sinclair Dunlop Director |
SELL
Open market or private sale
|
Direct |
500
-0.38%
|
$25,000
$50.7 P/Share
|
|
Jan 01
2023
|
Paul R. Fonteyne Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,867
+22.8%
|
-
|
|
Jan 01
2023
|
Gerald Chan Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,867
+32.32%
|
-
|
|
Jan 01
2023
|
Stephanie Monaghan O'Brien Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,867
+32.32%
|
-
|
|
Jan 01
2023
|
A. Sinclair Dunlop Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,867
+2.82%
|
-
|
|
Jan 01
2023
|
Alec Machiels Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,867
+1.42%
|
-
|